Triparna Sen

Triparna Sen

Auto-generated profile, based on publicly available information

Triparna Sen

Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2020 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
ÁQÁlvaro Quintanal-Villalonga
Álvaro Quintanal-Villalonga
JCJoseph M. Chan
Joseph M. Chan
HYHelena A. Yu
Helena A. Yu
DPDana Pe’er
Dana Pe’er
CSCharles L. Sawyers
Charles L. Sawyers
CRCharles M. Rudin
Charles M. Rudin

7 August 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
FUFathema Uddin
Fathema Uddin
CRCharles M. Rudin
Charles M. Rudin
TSTriparna Sen
Triparna Sen
A series of recent discoveries harnessing the adaptive immune system of prokaryotes to perform targeted genome editing is having a transformative influence across the biological sciences. The discovery of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (Cas) proteins has expanded the applications of genetic research in thousands of laboratories across the globe and is redefining our approach to gene therapy. Traditional gene therapy has raised some concerns, as its reliance on viral vector delivery of therapeutic transgenes can cause both insertional oncogenesis and immunogenic toxicity. While viral vectors remain a key delivery vehicle, CRISPR technology provides a relatively simple and efficient alternative for site-specific gene editing, obliviating some concerns raised by traditional gene therapy. Although it has apparent advantages, CRISPR/Cas9 brings its own set of limitations which must be addressed for safe and efficient clinical translation. This review focuses on the evolution of gene therapy and the role of CRISPR in shifting the gene therapy paradigm. We review the emerging data of recent gene therapy trials and consider the best strategy to move forward with this powerful but still relatively new technology.

5 April 2023 in Trends in Cancer
Verified
Journal Article
Open access
USUtsav Sen
Utsav Sen
CCCharles Coleman
Charles Coleman
TSTriparna Sen
Triparna Sen
Cancer progression is a highly balanced process and is maintained by a sequence of finely tuned metabolic pathways. Stearoyl coenzyme A desaturase-1 (SCD1), the fatty enzyme that converts saturated fatty acids into monounsaturated fatty acids, is a critical modulator of the fatty acid metabolic pathway. SCD1 expression is associated with poor prognosis in several cancer types. SCD1 triggers an iron-dependent cell death called ferroptosis and elevated levels of SCD1 protect cancer cells against ferroptosis. Pharmacological inhibition of SCD1 as monotherapy and in combination with chemotherapeutic agents shows promising antitumor potential in preclinical models. In this review, we summarize the role of SCD in cancer cell progression, survival, and ferroptosis and discuss potential strategies to exploit SCD1 inhibition in future clinical trials.

1 December 2020 in Cell Reports
Verified
Journal Article
Open access
CWCorrin A. Wohlhieter
Corrin A. Wohlhieter
ARAllison L. Richards
Allison L. Richards
FUFathema Uddin
Fathema Uddin
CHChristopher H. Hulton
Christopher H. Hulton
ÀQÀLvaro Quintanal-Villalonga
ÀLvaro Quintanal-Villalonga
CRCharles M. Rudin
Charles M. Rudin
Concurrent loss-of-function mutations in STK11 and KEAP1 in lung adenocarcinoma (LUAD) are associated with aggressive tumor growth, resistance to available therapies, and early death. We investigated the effects of coordinate STK11 and KEAP1 loss by comparing co-mutant with single mutant and wild-type isogenic counterparts in multiple LUAD models. STK11/KEAP1 co-mutation results in significantly elevated expression of ferroptosis-protective genes, including SCD and AKR1C1/2/3, and resistance to pharmacologically induced ferroptosis. CRISPR screening further nominates SCD (SCD1) as selectively essential in STK11/KEAP1 co-mutant LUAD. Genetic and pharmacological inhibition of SCD1 confirms the essentiality of this gene and augments the effects of ferroptosis induction by erastin and RSL3. Together these data identify SCD1 as a selective vulnerability and a promising candidate for targeted drug development in STK11/KEAP1 co-mutant LUAD.

1 July 2021 in Cancer Cell
Verified
Journal Article
Closed access
ACAndrew Chow
Andrew Chow
SSSara Schad
Sara Schad
MGMichael Green
Michael Green
MHMatthew D. Hellmann
Matthew D. Hellmann
VAViola Allaj
Viola Allaj
TMTaha Merghoub
Taha Merghoub

1 December 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
AQAlvaro Quintanal
Alvaro Quintanal
HTHirokazu Taniguchi
Hirokazu Taniguchi
YZYingqian A. Zhan
Yingqian A. Zhan
MHMaysun M. Hasan
Maysun M. Hasan
SCShweta S. Chavan
Shweta S. Chavan
TSTriparna Sen
Triparna Sen
Lineage plasticity is implicated in treatment resistance in multiple cancers. In lung adenocarcinomas (LUAD) amenable to targeted therapy, transformation to small cell lung cancer (SCLC) is a recognized resistance mechanism. Defining molecular mechanisms of neuroendocrine (NE) transformation in lung cancer has been limited by a paucity of pre/posttransformation clinical samples. Detailed genomic, epigenomic, transcriptomic, and protein characterization of combined LUAD/SCLC tumors, as well as pre/posttransformation samples, supports that NE transformation is primarily driven by transcriptional reprogramming rather than mutational events. We identify genomic contexts in which NE transformation is favored, including frequent loss of the 3p chromosome arm. We observed enhanced expression of genes involved in the PRC2 complex and PI3K/AKT and NOTCH pathways. Pharmacologic inhibition of the PI3K/AKT pathway delayed tumor growth and NE transformation in an EGFR-mutant patient-derived xenograft model. Our findings define a novel landscape of potential drivers and therapeutic vulnerabilities of NE transformation in lung cancer. Significance: The difficulty in collection of transformation samples has precluded the performance of molecular analyses, and thus little is known about the lineage plasticity mechanisms leading to LUAD-to-SCLC transformation. Here, we describe biological pathways dysregulated upon transformation and identify potential predictors and potential therapeutic vulnerabilities of NE transformation in the lung. See related commentary by Meador and Lovly, p. 2962. This article is highlighted in the In This Issue feature, p. 2945